nach oben

Inflammation Research

Erschienen in:

01.12.2010 | Original Research Paper

The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE₂ pathway

verfasst von: Li-xia Yang, Jin-shan Ye, Rui-wei Guo, Hong Liu, Xian-mei Wang, Feng Qi, Chuanming Guo

Erschienen in: Inflammation Research | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Aim

To explore the expression of extracellular matrix metalloproteinase inducer (EMMPRIN) in THP-1 macrophages induced by angiotensin II (Ang II) and the mechanism of EMMPRIN expression.

Methods

THP-1 cells were cultured and induced into macrophages, then stimulated with 10⁻⁶ mol/L Ang II. Levels of EMMPRIN gene and its protein were measured by real-time polymerase chain reaction and western blotting. Prostaglandin E₂ (PGE₂) expression was assayed by enzyme-linked immunosorbent assay. Antagonists of the angiotensin type-1 receptor (AT₁R) and angiotensin type-2 receptor (AT₂R) were used to inhibit the effect of Ang II, and PGE₂ added to detail the mechanism of Ang II-induced EMMPRIN expression.

Results

Ang II clearly induced the expression of EMMPRIN mRNA and protein in macrophages; this expression peaked at 12 h and declined after 24 h. The tendency of enhancement of the levels of cyclooxygenase-2 (COX-2) and PGE₂ was coincident with EMMPRIN expression. AT₁-receptor antagonists and COX-2 inhibitors inhibited the effect of Ang II, but AT₂-receptor antagonists did not.

Conclusion

Ang II can up-regulate EMMPRIN expression in THP-1 macrophages via the AT₁/COX-2/PGE₂ signal transduction pathway, and the effect can be inhibited by losartan and NS-398.

Kanekura T, Chen X, Kanzaki T. Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer. 2002;99:520–8.CrossRefPubMed

Biswas C, Zhang Y, DeCastro R, Guo H, Nakamura T, Kataoka H, et al. The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res. 1995;55:434–9.PubMed

Lim M, Martinez T, Jablons D, Cameron R, Guo H, Toole B, et al. Tumor-derived EMMPRIN (extracellular matrix metalloproteinase inducer) stimulates collagenase transcription through MAPK p38. FEBS Lett. 1998;441:88–92.CrossRefPubMed

Yang JM, Xu Z, Wu H, Zhu H, Wu X, Hait WN. Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Mol Cancer Res. 2003;1:420–7.PubMed

Major T, Liang L, Lu X. Extracellular matrix metalloproteinase inducer (EMMPRIN) is induced upon monocyte differentiation and is expressed in human atheroma. Arterioscler Thromb Vasc Biol. 2002;22:1200–7.CrossRefPubMed

Yoon YW, Kwon HM, Hwang KC, Choi EY, Hong BK, Kim D, et al. Upstream regulation of matrix metalloproteinase by EMMPRIN; extracellular matrix metalloproteinase inducer in advanced atherosclerotic plaque. Atherosclerosis. 2005;180:37–44.CrossRefPubMed

Hagemann T, Wilson J, Kulbe H. Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol. 2005;175:1197–205.PubMed

Abe N, Osanai T, Fujiwara T, Kameda K, Matsunaga T, Okumura K. C-reactive protein-induced upregulation of extracellular matrix metalloproteinase inducer in macrophages: inhibitory effect of fluvastatin. Life Sci. 2006;78:1021–8.CrossRefPubMed

Schmidt R, Bultmann A, Ungerer M. Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: implications in acute myocardial infarction. Circulation. 2006;113:834–41.CrossRefPubMed

10.

Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868–74.CrossRefPubMed

11.

Eldika N, Yerra L, Chi DS, Krishnaswamy G. Atherosclerosis as an inflammatory disease: implications for therapy. Front Biosci. 2004;9:2764–77.CrossRefPubMed

12.

McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001;86:746–56.PubMed

13.

Cipollone F, Cicolini G, Bucci M. Cyclooxygenase and prostaglandin synthases in atherosclerosis: recent insights and future perspectives. Pharmacol Ther. 2008;118:161–80.CrossRefPubMed

14.

Cipollone F, Fazia M, Mezzetti A. Novel determinants of plaque instability. J Thromb Haemost. 2005;3:1962–75.CrossRefPubMed

15.

Cipollone F, Rocca B, Patrono C. Cyclooxygenase-2 expression and inhibition in atherothrombosis. Arterioscler Thromb Vasc Biol. 2004;24:246–55.CrossRefPubMed

16.

Koki A, Khan NK, Woerner BM, Dannenberg AJ, Olson L, Seibert K, et al. Cyclooxygenase-2 in human pathological disease. Adv Exp Med Biol. 2002;507:177–84.PubMed

17.

Cipollone F, Prontera C, Pini B, Marini M, Fazia M, De Cesare D, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921–7.CrossRefPubMed

18.

Cipollone F, Fazia M, Iezzi A, Zucchelli M, Pini B, De Cesare D, et al. Suppression of the functionally coupled cyclooxygenase-2/prostaglandin E synthase as a basis of simvastatin-dependent plaque stabilization in humans. Circulation. 2003;107:1479–85.CrossRefPubMed

19.

Cipollone F, Fazia M, Iezzi A, Pini B, Cuccurullo C, Zucchelli M, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation. 2004;109:1482–8.CrossRefPubMed

20.

Yusuf S, Sleiht P, Pogue J. The Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145–53.CrossRefPubMed

21.

Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995–1003.CrossRefPubMed

22.

Fox K. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782–7.CrossRefPubMed

23.

Schieffer B, Schieffer E, Hilfiker-Kleiner D. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation. 2000;101:1372–8.PubMed

24.

Ohnaka K, Numaguchi K, Yamakawa T, Inagami T. Induction of cyclooxygenase-2 by angiotensin II in cultured rat vascular smooth muscle cells. Hypertension. 2000;35:68–75.PubMed

25.

Brilla CG, Zhou G, Rupp H, Maisch B, Weber KT. Role of angiotensin II and prostaglandin E2 in regulating cardiac fibroblast collagen turnover. Am J Cardiol. 1995;76:8D–13D.CrossRefPubMed

26.

Park EK, Jung HS, Yang HI, Yoo MC, Kim C, Kim KS. Optimized THP-1 differentiation is required for the detection of responses to weak stimuli. Inflamm Res. 2007;56:45–50.CrossRefPubMed

27.

Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000;101:1586–93.PubMed

28.

Blessing E, Preusch M, Kranzhofer R, Kinscherf R, Marx N, Rosenfeld ME, et al. Anti-atherosclerotic properties of telmisartan in advanced atherosclerotic lesions in apolipoprotein E deficient mice. Atherosclerosis. 2008;199:295–303.CrossRefPubMed

29.

Ayabe N, Babaev VR, Tang Y, Tanizawa T, Fogo AB, Linton MF, et al. Transiently heightened angiotensin II has distinct effects on atherosclerosis and aneurysm formation in hyperlipidemic mice. Atherosclerosis. 2006;184:312–21.CrossRefPubMed

30.

Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest. 2000;105:1605–12.CrossRefPubMed

31.

Ikeda U, Shimada K. Matrix metalloproteinases and coronary artery diseases. Clin Cardiol. 2003;26:55–9.CrossRefPubMed

32.

Luchtefeld M, Grote K, Grothusen C, Bley S, Bandlow N, Selle T, et al. Angiotensin II induces MMP-2 in a p47phox-dependent manner. Biochem Biophys Res Commun. 2005;328:183–8.CrossRefPubMed

33.

Guo RW, Yang LX, Wang H, Liu B, Wang L. Angiotensin II induces matrix metalloproteinase-9 expression via a nuclear factor-kappaB-dependent pathway in vascular smooth muscle cells. Regul Pept. 2008;147:37–44.CrossRefPubMed

34.

Crofford LJ. COX-1 and COX-2 tissue expression: implications and predictions. J Rheumatol Suppl. 1997;49:15–9.PubMed

35.

Hong BK, Kwon HM, Lee BK, Kim D, Kim IJ, Kang SM, et al. Coexpression of cyclooxygenase-2 and matrix metalloproteinases in human aortic atherosclerotic lesions. Yonsei Med J. 2000;41:82–8.PubMed

36.

Burleigh ME, Babaev VR, Oates JA, Harris RC, Gautam S, Riendeau D, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816–23.CrossRefPubMed

37.

Burleigh ME, Babaev VR, Yancey PG, Major AS, McCaleb JL, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in ApoE-deficient and C57BL/6 mice. J Mol Cell Cardiol. 2005;39:443–52.CrossRefPubMed

38.

Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 1997;272:24–7.CrossRefPubMed

39.

Spinale FG, Coker ML, Heung LJ. A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation. 2000;102:1944–9.PubMed

40.

Spinale FG, Coker ML, Bond BR, Zellner JL. Myocardial matrix degradation and matrix metalloproteinase activation in the failing heart: a potential therapeutic target. Circ Res. 2000;46:225–38.

41.

Brown DL, Desai KK, Vakili BA. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol. 2004;24:733–8.CrossRefPubMed

Titel: The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway
verfasst von: Li-xia Yang
Jin-shan Ye
Rui-wei Guo
Hong Liu
Xian-mei Wang
Feng Qi
Chuanming Guo
Publikationsdatum: 01.12.2010
Verlag: SP Birkhäuser Verlag Basel
Erschienen in: Inflammation Research / Ausgabe 12/2010
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI: https://doi.org/10.1007/s00011-010-0223-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

SGLT2-Inhibitoren und GLP-1-Rezeptoragonisten im Schlagabtausch

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Wer hat die Nase vorn – SGLT2-Inhibitoren oder GLP-1-Rezeptoragonisten? Diese Frage diskutierten zwei Experten in einer Session auf dem diesjährigen Diabetes-Kongress.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Delir bei kritisch Kranken – Antipsychotika versus Placebo

16.05.2024 Delir nicht substanzbedingt Nachrichten

Um die Langzeitfolgen eines Delirs bei kritisch Kranken zu mildern, wird vielerorts auf eine Akuttherapie mit Antipsychotika gesetzt. Eine US-amerikanische Forschungsgruppe äußert jetzt erhebliche Vorbehalte gegen dieses Vorgehen. Denn es gibt neue Daten zum Langzeiteffekt von Haloperidol bzw. Ziprasidon versus Placebo.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Aim

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

“Old drugs” for the treatment of rheumatoid arthritis: will the cholinergic anti-inflammatory pathway and anti-nociceptive pathway work?

Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells

Helicobacter pylori: a ROS-inducing bacterial species in the stomach

Amebic monocyte locomotion inhibitory factor peptide ameliorates inflammation in CIA mouse model by downregulation of cell adhesion, inflammation/chemotaxis, and matrix metalloproteinases genes

Efficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysis